HC Wainwright Lowers Earnings Estimates for Aethlon Medical

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Aethlon Medical in a research report issued on Tuesday, February 17th. HC Wainwright analyst S. Ramakanth now anticipates that the medical equipment provider will earn ($9.49) per share for the year, down from their previous estimate of ($9.00). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.61) EPS and FY2030 earnings at ($0.30) EPS.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($0.44).

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Stock Down 1.4%

Shares of NASDAQ:AEMD opened at $2.09 on Thursday. The company has a market cap of $2.76 million, a price-to-earnings ratio of -0.09 and a beta of 1.60. The firm’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $6.02. Aethlon Medical has a fifty-two week low of $1.86 and a fifty-two week high of $52.79.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Aethlon Medical

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright sharply raised EPS forecasts for multiple 2027 quarters and for FY2027–FY2030, cutting expected per‑quarter losses (e.g., Q1–Q4 2027 revisions from roughly ($1.40) to about ($0.23)–($0.26)) and projecting much smaller annual losses by 2028–2030 — this signals the analyst sees a clearer path to reduced losses and improves medium‑term outlook. MarketBeat AEMD report
• Positive Sentiment: Company clinical progress: a Yahoo Finance piece highlights Aethlon advancing an oncology trial and exploring broader/simpler device applications — any positive trial readouts or clear regulatory progress would be a catalyst for the thin‑ly traded microcap. AEMD: Advancing Oncology Trial
• Neutral Sentiment: Reported short‑interest data for mid‑February appears inconsistent (shows zero shares / NaN changes and a 0.0 days‑to‑cover figure). The noisy/unclear short‑interest reporting reduces its usefulness as a signal for immediate price pressure.
• Negative Sentiment: HC Wainwright lowered FY2026 and Q4‑2026 EPS (Q4‑2026 cut from $3.00 to ($2.44), FY2026 to ($9.49)), underscoring significant near‑term weakness and continued large losses; near‑term fundamentals remain challenged and prior quarterly results showed a big EPS miss. MarketBeat AEMD report

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.